Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesDermatologyAetna hypertrophic scars keloids Coverage | OpenPa…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentAetnaPolicy 0389

    Hypertrophic Scars and Keloids

    Customize your policy alerts

    Sign up for Aetna Policy 0389 alerts

    Get alerted when Policy 0389 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines Aetna's medical necessity and experimental/investigational determinations for interventions to treat hypertrophic scars and keloids, and lists associated CPT/HCPCS/ICD-10 codes; applies to Aetna members/providers.

    Policy Summary
    PayerAetna
    PolicyHypertrophic Scars and Keloids
    Policy CodePolicy 0389
    Change TypeNo material change
    Effective DateOct 4, 2000
    Last ReviewJun 22, 2023
    Next Review DateApr 11, 2024
    Key ActionDocument failure of conservative therapies and objective scar assessments before requesting coverage for fractional ablative laser.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2Medically necessary categories
    34+Experimental/investigational items
    17110,0479TExample CPT codes
    06/22/2023Last review

    Coverage Criteria

    Medical Necessity — Aetna considers the following interventions medically necessary:

    Medical Necessity — Aetna considers the following interventions medically necessary:

    Intralesional 5‑fluorouracil, cryotherapy, or intralesional corticosteroids for treatment of keloids when medical necessity criteria for keloid removal are met (see CPB 0031 - Cosmetic Surgery for medically necessary indications for keloid removal).
    Fractional ablative laser for the treatment of burn scars, traumatic scars, and post‑surgical scars when ALL of the following are met: documented evidence of significant functional impairment related to scars (e.g., limited movement); and the member has tried and failed conventional treatments (e.g., hypoallergenic paper tape, or silicone gel/sheeting).

    Fractional Ablative Laser — Covered when ALL of the following are met:

    Fractional Ablative Laser — Covered when ALL of the following are met:

    Scar is a burn scar, traumatic scar, or post‑surgical scar.
    Documented significant functional impairment related to the scar (for example, limited range of motion).

    Coding

    CPT Codes Not Covered / RelatedCPTNot Covered
    15769Grafting of autologous soft tissue, other, harvested by direct excision (e.g., fat, dermis, fascia)
    15771Grafting of autologous fat harvested by liposuction technique to trunk, breasts, scalp, arms, and/or legs; 50 cc or less injectate
    99183Physician or other qualified health care professional attendance and supervision of hyperbaric oxygen therapy, per session
    11042-11047Debridement; subcutaneous tissue, muscle/fascia, bone (related CPT debridement codes)
    HCPCS/Drug Codes (mixed — covered or not covered as specified)HCPCS
    J0702Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg
    J3300Injection, triamcinolone acetonide, preservative free, 1 mg
    J9190Fluorouracil, 500 mg
    J9040Injection, bleomycin sulfate, 15 units
    J0585Injection, onabotulinumtoxinA, 1 unit [Botox] (listed as not covered for indications in CPB)
    A6025Gel sheet for dermal or epidermal application (e.g., silicone), each (listed as not covered)
    ICD-10 Diagnosis Codes (covered if selection criteria met)ICD-10Covered
    L90.5Scar conditions and fibrosis of skin
    L91.0Hypertrophic scar [keloid]
    Covered CPT Codes (if selection criteria met)CPTCovered
    17110Destruction (e.g., laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), of benign lesions other than skin tags or cutaneous vascular proliferative lesions; up to 14 lesions [covered for keloid scar documented to be painful, ulcerated, pruritic causing a functional impairment (i.e. restricted movement)]
    17111Destruction of benign lesions; 15 or more lesions [keloid scars]
    11900Injection, intralesional; up to and including 7 lesions [corticosteroids]
    11901Injection, intralesional; more than 7 lesions [corticosteroids]
    0479TFractional ablative laser fenestration of burn and traumatic scars for functional improvement; first 100 cm2 or part thereof, or 1% of body surface area of infants and children
    0480TFractional ablative laser; each additional 100 cm2, or each additional 1% of body surface area of infants and children, or part thereof (List separately in addition to code for primary procedure)

    Provider Actions and Authorization

    Prior Authorization

    Prior Authorization for Fractional Ablative Laser

    Prior authorization may be required for fractional ablative laser (CPT 0479T, 0480T) when used for burn, traumatic, or post‑surgical scars. Authorization is generally considered only when documentation shows significant functional impairment (for example, restricted movement) and prior trial and failure of conventional conservative therapies (e.g., hypoallergenic paper tape, silicone gel/sheeting, pressure garments) have been attempted and documented.

    • Affected codes: 0479T, 0480T
    • Document trial and failure of conservative therapies (see documentation callout)
    Prior Authorization

    BTX‑A Prior Authorization Consideration

    Botulinum toxin A (BTX‑A) injections have RCTs and meta‑analyses reporting improvements in scar width, VSS/VAS scores, and patient satisfaction; prior authorization may be considered on a case‑by‑case basis depending on plan benefits and submitted evidence.

    • Evidence: multiple RCTs and meta‑analyses (e.g., Zhang 2016; Qiao 2021)

    Background

    Background and pathophysiologic context note that keloids and hypertrophic scars result from dermal tissue proliferation after skin injury and that laser therapies, pressure therapy, intralesional agents, and surgical approaches have varying levels of evidence; the policy’s evidence summaries and cited studies provide clinical context but do not replace individual plan coverage rules.

    Keloids and hypertrophic scars are described as abnormal dermal proliferations arising after skin injury; epidemiologic estimates in background sections indicate these lesions occur in a minority of wounds, and common first‑line or adjunctive therapies include silicone gel sheeting and intralesional corticosteroids, while many novel or device‑based interventions remain investigational.

    Definitions

    Silicone gel sheeting — definition and typical use
    DefinitionSoft, slightly adherent, semi-occlusive covering fabricated from medical-grade silicone polymers used to reduce scar volume and improve elasticity of hypertrophic and keloid scars; available as sheets, gels, or rigid shells (OTC brands: Sil-K, Cica-Care, ReJuveness, DuraSil, Silastic; Epi-Derm prescription).
    Typical useApplied to scars (donor/recipient sites, burns) as a dressing or adjunctive therapy to improve appearance and symptoms (pruritus, burning pain) and to increase scar elasticity.
    Evidence summaryCase series report improvements in scar size, erythema, elasticity and symptoms, but prospective randomized controlled trials are limited and results are inconsistent compared with standard wound dressings.
    Formulations/examplesGel sheeting, topical silicone gel, custom-molded rigid shells; examples include Sil-K, Cica-Care, ReJuveness, DuraSil, Silastic, and Epi-Derm.
    Intralesional therapy — definition (agents like corticosteroids, 5-FU)

    Revision History

    2000-10-04effective_date

    Policy became effective.

    2023-06-22last_reviewLatest

    Policy last reviewed.

    2024-04-11next_scheduled_review

    Next scheduled policy review date per Clinical Policy Bulletin governance.

    Policy Summary
    PayerAetna
    PolicyHypertrophic Scars and Keloids
    Policy CodePolicy 0389
    Change TypeNo material change
    Effective DateOct 4, 2000
    Last ReviewJun 22, 2023
    Next Review DateApr 11, 2024
    Key ActionDocument failure of conservative therapies and objective scar assessments before requesting coverage for fractional ablative laser.
    SourceLink
    On This Page
    Coverage CriteriaCodingProvider Actions and AuthorizationBackgroundDefinitionsRevision History
    Failure of conservative conventional treatments (for example, hypoallergenic paper tape, silicone gel/sheeting).

    Experimental and Investigational — Interventions considered experimental/investigational for hypertrophic scars or keloids

    Experimental and Investigational — Aetna considers the following interventions experimental and investigational for hypertrophic scars or keloids because the effectiveness has not been established:

    Adipose‑derived stem cell
    Adipose‑derived stromal vascular fraction
    Anti‑vascular endothelial growth factor therapy (e.g., bevacizumab)
    Autologous fat grafting
    Basic fibroblast growth factor
    Calcium antagonists
    Combined micro‑plasma radiofrequency with hypo‑fractionated electron‑beam radiation
    Dermal substitutes
    Etanercept
    Extracorporeal shock wave therapy
    Growth hormone‑releasing peptide 6
    Hyaluronidase
    Hyperbaric oxygen therapy
    Imiquimod cream
    Intense pulsed light
    Interferon alpha
    Interleukin‑10
    Intermittent magnetic pressure therapy
    Intralesional bleomycin
    Intralesional botulinum toxin type A injection
    Intralesional fiber laser device (for keloids)
    Intralesional mitomycin
    Laser‑assisted drug delivery (e.g., administration of corticosteroid)
    Losartan ointment
    Mesenchymal stem cells
    Micro‑needling (with Dermapen disposable tips or other devices/tools)
    Non‑ablative fractional laser
    Photodynamic therapy
    Radiofrequency treatment (including plasma radiofrequency ablation)
    Silicone products (e.g., gel, rigid shells, sheeting)
    Topical calcipotriol
    Topical oxandrolone
    Topical retinoids
    Transforming growth factor beta1

    Evidence summaries by therapy — Evidence summaries and comparative outcomes from systematic reviews, meta‑analyses, RCTs, animal and in‑vitro studies

    Evidence summaries by therapy — Evidence summaries and comparative outcomes from systematic reviews, meta‑analyses, RCTs, animal and in‑vitro studies:

    Fractional ablative laser (AFL): Multiple prospective cohort studies, randomized trials, systematic reviews and large observational series report improvements in objective scar scales (e.g., VSS, POSAS, Manchester Scar Scale), symptom scores (pain, pruritus), scar thickness, and patient‑reported quality of life for burn, traumatic and post‑surgical scars. Studies vary in design, timing of treatment (early vs delayed), laser type (CO2, Er:YAG), and outcomes; heterogeneity limits pooled estimates. International consensus and guideline sources note AFL shows promise but that higher‑quality RCTs and standardized protocols are needed.
    Early/Prophylactic Laser: RCTs and reviews of early laser (within 3 months of injury or within 6 months after surgery) show mixed results; some split‑scar RCTs favor laser on certain scales while overall heterogeneity and inconsistent reporting render conclusions uncertain.
    Non‑ablative fractional laser (NAFL): Comparative split‑scar randomized trial found no statistically significant difference in observer scores between NAFL and AFL; patient satisfaction was high with both modalities but AFL associated with greater pain.
    Botulinum toxin (BTX): Systematic reviews and meta‑analyses of small, heterogeneous RCTs report some improvements in scar width, VAS, and patient satisfaction for facial/neck scars, but methodological limitations, variability in dosing/technique, and small sample sizes preclude definitive conclusions. Further large, standardized RCTs are required.
    Calcium antagonists (e.g., verapamil): Meta‑analyses and trials report mixed results; some trials suggest comparable effects to corticosteroids but higher risk of bias and an RCT demonstrated higher recurrence with verapamil versus triamcinolone after excision, leading to conclusion that verapamil is safe but not clearly superior.
    Imiquimod 5% cream: Case series and small RCTs show highly variable recurrence rates after excision; a meta‑analysis showed very low certainty and inconsistent results (overall high variability by location), and imiquimod is not recommended as a reliable therapy.
    Laser‑assisted drug delivery: Systematic review of RCTs found heterogeneity across small trials; evidence insufficient to recommend routine use and larger, high‑quality RCTs are needed.
    Autologous fat grafting and adipose‑derived stromal vascular fraction: Case series and low‑quality studies report potential improvements in scar quality and symptoms, but evidence is limited to small, uncontrolled studies and controlled trials are lacking.
    Anti‑VEGF (bevacizumab): Preclinical (animal) data suggest reduction in hypertrophic scarring; no published clinical data on local/topical bevacizumab for scars.
    Interleukin‑10, photodynamic therapy, plasma radiofrequency ablation, extracorporeal shock wave therapy, hyperbaric oxygen therapy, mesenchymal stem cells, magnetic pressure therapy and other listed investigational modalities: Evidence is preliminary (in‑vitro, animal studies, small case series or pilot trials) and insufficient to establish safety and effectiveness in humans; further well‑designed clinical trials are required.
    Pressure therapy and intralesional corticosteroids: Systematic reviews support pressure therapy for burn hypertrophic scars and intralesional triamcinolone as standard non‑surgical management with evidence for improvements in scar parameters; combination approaches (surgery + adjuvant therapy) are commonly used for keloids with variable recurrence rates depending on modality and location.

    Background evidence (no coverage criteria in this excerpt)

    Background evidence (no coverage criteria in this excerpt) — key study findings and context:

    ThermaCool radiofrequency: Small uncontrolled study found collagen morphology changes but no clinical improvement in hypertrophic scars or keloids; ThermaCool alone did not achieve clinical benefit.
    Interferon alpha‑2b: Prospective study found higher recurrence when used post‑excision compared with triamcinolone; concluded not effective.
    Pressure therapy: Meta‑analysis of RCTs in burn patients showed improvements in VSS and scar characteristics for 15–25 mmHg; study limitations noted.
    Extracorporeal shock wave therapy, plasma radiofrequency ablation, and other novel device‑based approaches: Animal and small human studies exist with mixed outcomes; keloid patients were often excluded from small P‑RF studies due to poor results.
    Hyperbaric oxygen therapy: Small meta‑analysis suggests reduced recurrence after surgery/radiotherapy and improved VSS and satisfaction, but limited number and quality of trials necessitate further research.
    MAIT cell percentage and other biomarkers: Emerging translational research suggests potential diagnostic biomarkers (e.g., reduced MAIT cells in keloid patients) but clinical utility is not established.
    Clinical practice guidance and reviews: International guidelines and UpToDate summarize that laser therapy (especially fractional ablative) may be useful in selected scars, particularly when conservative measures fail, but they classify some laser approaches as investigational or with limited supporting evidence and call for additional RCTs and standardized outcome reporting.
  1. Consider documenting scar location, prior treatments, and objective measures
  2. Prior Authorization

    Prior Authorization for AFL Procedures

    Given evolving practice patterns and evidence that CO2‑AFL has been associated with reduced length of stay and anesthetic time in some series, prior authorization for ablative fractional laser (AFL) procedures may require additional clinical documentation supporting medical necessity and that conservative measures were tried.

    • Document expected clinical benefit and prior conservative therapy
    • Consider operative/anesthesia implications when determining authorization
    Prior Authorization

    Authorization Likely for Radiotherapy and HBOT

    Authorization is likely for excision with adjuvant radiotherapy and for hyperbaric oxygen therapy (HBOT) when supported by clinical documentation consistent with the Clinical Policy Bulletin and plan benefits.

    • Radiotherapy for chest keloids: recurrence data support use as adjuvant therapy
    • HBOT: meta‑analysis suggests reduced recurrence after surgery/radiotherapy
    Prior Authorization

    Prior Authorization per Clinical Policy Bulletin

    Coverage and prior authorization requirements are governed by this Clinical Policy Bulletin and the member's individual plan benefits. Providers should follow Aetna procedures for submitting prior authorization requests and supporting documentation.

    • Follow Clinical Policy Bulletin procedures and individual plan benefits
    • Prior authorization determinations depend on submitted documentation and plan terms
    Note

    Prior Authorization Not Specified in This Section

    This section does not specify universal prior authorization triggers for all listed interventions. Some therapies may be subject to prior authorization depending on plan benefits, coding, and whether interventions are considered experimental/ investigational for the indication.

    • Not all interventions in this section have explicit prior authorization rules
    • Check member's plan documents for applicability
    Note

    Background Evidentiary Implications

    The evidence base includes heterogeneous study designs, variable quality, and evolving literature; experimental or insufficient evidence for some therapies increases the risk of denial if clinical justification or high‑quality supporting data are not provided.

    • Heterogeneity and low quality of some trials may affect authorization decisions
    • Experimental/insufficient evidence treatments (see policy list) are at higher denial risk
    Note

    Verapamil vs Triamcinolone Recurrence Risk

    A randomized split‑scar RCT showed higher keloid recurrence with verapamil compared with intralesional triamcinolone (hazard ratio 8.44); verapamil was safe but less effective, and the trial was terminated early for inferiority. This impacts expectations for verapamil as an alternative to corticosteroids.

    • Study: Danielsen et al (2016) — verapamil vs triamcinolone; higher recurrence with verapamil
    • Implication: document rationale if verapamil is used instead of triamcinolone
    Denial Risk

    P‑RF for Keloids Excluded in Reported Series

    Patients with keloids were excluded from reported plasma radiofrequency (P‑RF) ablation series due to unsatisfactory results; P‑RF for keloids lacks supportive evidence and may be considered unsuitable or experimental for keloid treatment.

    • P‑RF studies excluded keloid patients due to poor outcomes
    • Treating providers should document rationale if using P‑RF in atypical cases
    Denial Risk

    Experimental / Insufficient Evidence Risk

    Therapies listed as experimental or investigational in this policy (e.g., adipose‑derived stem cell therapy, intralesional botulinum toxin for keloids, dermal substitutes, extracorporeal shock wave therapy) carry an increased risk of denial due to insufficient evidence; provide robust clinical justification and supporting literature if requesting coverage.

    • Refer to policy's Experimental and Investigational list for non‑covered interventions
    • Submit peer‑reviewed evidence if requesting exception
    Note

    No Explicit Authorization or Denial Triggers

    There are no explicit automatic authorization or denial triggers listed in these supplemental provider‑actions; decisions are determined by plan benefits, evidence quality, and the adequacy of submitted clinical documentation.

    • Authorization decisions are individualized
    • Lack of explicit triggers means documentation quality drives decisions
    Documentation Required

    Suggested Clinical Documentation

    Suggested clinical documentation to support prior authorization requests includes objective scar severity assessments (e.g., Vancouver Scar Scale, Manchester Scar Scale, POSAS, UNC4P), standardized pre‑ and post‑treatment photographs, description of functional impairment, dates and details of prior treatments, response to prior therapies, and proposed treatment plan (dose, frequency, and number of sessions).

    • Include validated scar scores (VSS, POSAS, Manchester Scar Scale, UNC4P)
    • Provide dated photos, prior treatment history, and objective measures of functional impairment
    • For intralesional corticosteroids document concentration, intervals, and number of treatments
    Step Therapy

    Combination, First‑Line, and Stepwise Approach / Conservative Therapies Prior to Advanced Interventions

    A stepwise, combination and conservative approach is reflected in the evidence: intralesional corticosteroids (triamcinolone) are a preferred first‑line non‑surgical therapy; combination therapies (e.g., surgery plus intralesional steroid, cryosurgery plus steroid) are commonly used; and conservative measures (silicone sheeting, pressure therapy, hypoallergenic tape, onion extract) are often recommended prior to advanced interventions such as laser or surgery.

    • Preferred first‑line: intralesional triamcinolone (10–40 mg/mL)
    • Conservative therapies trial: silicone gel/sheeting and pressure therapy for 8–12 weeks where applicable
    • Combination therapies are frequently used and supported by some studies
    Note

    Provider Resources and Links

    Providers may find additional resources and links on Aetna's site for policy details, glossary, mobile app, FAQs, and program provisions. Use these resources and the Clinical Policy Bulletin for guidance on benefits, submission procedures, and administrative questions.

    • Aetna Clinical Policy Bulletin Notes and plan‑specific procedures
    • Glossary: https://www.aetna.com/glossary.html
    • Aetna Mobile App: https://www.aetna.com/individuals-families/using-your-aetna-benefits/aetna-mobile.html
    • FAQs and Program Provisions available on Aetna website
    DefinitionInjection of therapeutic agents directly into keloid or hypertrophic scar tissue to reduce scar size and symptoms.
    Common agentsCorticosteroids (e.g., triamcinolone acetonide) and antimetabolites (e.g., 5-fluorouracil) — used alone or in combination with other modalities (e.g., pulsed-dye laser).
    Purpose/mechanismAims to soften and flatten scars by inhibiting fibroblast proliferation and collagen synthesis; corticosteroids also reduce inflammation and pruritus.
    EvidenceMultiple clinical trials demonstrate effectiveness of intralesional 5-FU and combinations (TA + 5-FU ± PDL) with higher improvement rates than steroid alone in some studies.
    intralesional therapy (synonym entry)
    TermIntralesional therapy (synonym entry)
    Short definitionDirect injection of agents into scar tissue (e.g., corticosteroids, 5-FU) to reduce scar volume and symptoms.
    ContextUsed as standard non-surgical management and often combined with other modalities in clinical practice and trials.
    NAFL — Non-ablative fractional laser definition
    DefinitionNon-ablative fractional laser (NAFL) — a noninvasive laser approach that creates columns of thermal injury to remodel dermal tissue without full-thickness epidermal ablation.
    Mechanism/goalStimulates dermal remodeling and collagen reorganization while preserving epidermal continuity, often with lower downtime and pain than ablative lasers.
    Examples/ wavelengthsExamples include erbium:glass (1,550 nm) and thulium (1,927 nm) NAFL systems, often combined with PDL for vascular components.
    EvidenceRCTs and split‑scar trials show mixed objective improvements; some patient-reported benefits despite limited blinded observer confirmation.
    Pathogenesis theories — proposed mechanisms for keloid formation
    Proposed mechanismsIschemia theory — abnormal blood flow/angiogenesis contributing to scar overgrowth.
    Inflammatory/immune interactionsImmune theory and TGF-β interactions — dysregulated growth factor signaling (e.g., TGF-β) and immune responses promote collagen overproduction.
    Cellular contributorsMast cell theory — mast cell activation driving fibrosis; alterations in collagen turnover and fibroblast activity.
    Mechanical/genetic factorsMechanical theory — tension alignment and mechanical forces influence scar shape and growth; genetic predisposition also implicated.
    Anti-VEGF therapy (e.g., bevacizumab) — experimental approach
    ApproachAnti-VEGF therapy (e.g., bevacizumab) aims to inhibit angiogenesis implicated in hypertrophic scar formation by reducing VEGF activity.
    Preclinical evidenceIn rabbit ear models, bevacizumab reduced scar elevation index, VEGF levels, and vessel counts compared with saline (statistically significant differences reported).
    Clinical statusNo published studies on local injection or topical application to human scars; clinical safety and effectiveness remain unestablished.
    Vancouver Scar Scale (VSS) — clinician-rated scar scale
    DefinitionVancouver Scar Scale (VSS) — an objective clinician‑rated scale assessing pigmentation, vascularity (erythema), pliability, and height (thickness) to quantify scar severity and response.
    Use in studiesUsed widely in laser and scar intervention studies as a primary objective outcome measure for pigmentation, erythema, pliability, and height changes.
    InterpretationLower VSS scores indicate improvement; changes used to document treatment effect in cohort and randomized studies.
    Ablative fractional laser (AFL) — definition and examples (CO2, Er:YAG)
    DefinitionAblative fractional laser (AFL) — a laser modality that creates microthermal zones of full‑thickness ablation in the epidermis and dermis to stimulate dermal remodeling and improve scar thickness, texture, and pigmentation.
    ExamplesCommon AFL systems include fractional CO2 and Er:YAG (Er:YAG may show favorable molecular remodeling in preclinical models).
    Clinical useUsed for hypertrophic burn and post‑surgical scars to improve objective measures (VSS, thickness) and symptoms (pain, pruritus); may require multiple sessions.
    Non-ablative fractional laser (NAFL) — definition and examples
    DefinitionNon‑ablative fractional laser (NAFL) — a fractional laser that produces dermal thermal remodeling without full‑thickness epidermal ablation to target scar texture and pigmentation with lower downtime.
    ExamplesExamples in studies include 1,550 nm erbium:glass and 1,927 nm thulium NAFL systems, sometimes combined with PDL for vascularity control.
    Clinical findingsSplit‑scar RCTs report mixed objective findings; patients may report improved appearance though blinded physician assessments are sometimes non‑significant.
    Indications for laser therapy — typical indications
    Typical indicationsImmature or linear hypertrophic erythematous scars persisting >1 month despite preventive treatment (silicone gel/sheeting, hypoallergenic tape, onion extract).
    Widespread burn scarsWidespread hypertrophic burn scars that have failed conservative therapy (silicone gel/sheeting, pressure garments, onion extract) for 8–12 weeks are candidates for laser therapy.
    Symptomatic or functional scarsScars causing persistent erythema, pain, pruritus, or functional limitation (e.g., contracture limiting movement) may be considered for laser modalities when conservative measures fail.
    Documentation requirementObjective scar assessments (e.g., VSS, POSAS), photographic documentation, and documentation of failed conservative therapy are recommended to support candidacy.
    Intralesional triamcinolone acetonide (TAC) — dosing and mechanism
    Agent and dosingIntralesional triamcinolone acetonide (TAC) — commonly used at concentrations of 10 to 40 mg/mL administered intralesionally.
    MechanismCorticosteroids soften and flatten scars by diminishing collagen and glycosaminoglycan synthesis and inhibiting fibroblast proliferation; anti‑inflammatory and vasoconstrictive effects reduce pain and pruritus.
    Treatment intervalTreatments are usually repeated every 4 to 6 weeks; optimal concentration and number of treatments are not definitively established.
    Role in stepwise careDescribed as the standard non‑surgical therapy and often expected to be tried before advanced or experimental modalities.
    Hyperbaric oxygen therapy (HBOT) — definition and reported effects
    DefinitionHyperbaric oxygen therapy (HBOT) — breathing pure or high‑concentration oxygen at pressures above atmospheric in an enclosed chamber to enhance tissue oxygenation.
    Reported effectsMeta-analysis of selected studies (4 included: 1 RCT, 1 CCT, 2 cohorts) reported reduced recurrence after surgery/radiotherapy (OR 0.26), increased patient satisfaction (OR 4.45), and improved VSS scores (SMD -3.82).
    Evidence caveatAvailable studies are limited (small number selected from many publications); authors call for more RCTs and longer‑term data to confirm findings and safety.